SGLT2 Inhibitors in Cardiovascular Diseases: Mechanisms, Clinical Impact, and Future Directions reviews the impact of SGLT2 inhibitors on cardiovascular health in individuals with type 2 diabetes, chronic kidney disease, heart failure, and atherosclerosis. The book synthesizes preclinical and clinical evidence to highlight the cardiovascular benefits of these drugs, initially developed for hyperglycemia management. It details recent studies on SGLT2 inhibitors' effects on cognitive dysfunction, sudden death, ventricular arrhythmias, heart remodeling, and cancer risks in diabetic patients.
In addition, it compares SGLT2 inhibitors with DPP4 inhibitors, emphasizing the efficacy of empagliflozin and dapagliflozin in reducing syncope and cardiovascular mortality, supported by trials like EMPA-REG OUTCOME and DECLARE-TIMI 58. Addressing a gap in literature, the book provides a comprehensive overview of SGLT2 inhibitors' cardiovascular benefits in high-risk populations, including atrial fibrillation and syncope. It offers valuable insights and recommendations for clinicians, researchers, and policymakers managing cardiovascular risk.
- Offers an in-depth review of the cardiovascular benefits of SGLT2 inhibitors that is supported by both preclinical and clinical evidence
- Emphasizes the importance of comparing SGLT2 inhibitors with other diabetes medications, such as DPP4 inhibitors, to showcase their superior efficacy in reducing cardiovascular risks
- Explores less commonly discussed outcomes like atrial fibrillation and syncope
